Summary: In 6263 patients with heart failure and a left ventricular ejection fraction above 40%, dapagliflozin 10 mg reduced worsening heart failure or cardiovascular death compared with placebo (16.4% vs 19.5%; hazard ratio 0.82; 95% CI 0.73 to 0.92) over a median of 2.3 years. Cardiovascular death alone was not significantly reduced (hazard ratio 0.88; 95% CI 0.74 to 1.05).
PICO Summary
| Element | Detail |
|---|---|
| Population | 6263 patients with heart failure and a left ventricular ejection fraction above 40% (mildly reduced or preserved), with or without diabetes; randomised, placebo-controlled trial; median follow-up 2.3 years. |
| Intervention | Dapagliflozin 10 mg once daily added to usual therapy (n=3131). |
| Comparison | Matching placebo added to usual therapy (n=3132). |
| Outcome | Worsening heart failure (unplanned hospitalisation or urgent visit for heart failure) or cardiovascular death: 512 (16.4%) vs 610 (19.5%); HR 0.82 (95% CI 0.73 to 0.92); p<0.001. Worsening heart failure: 368 (11.8%) vs 455 (14.5%); HR 0.79 (95% CI 0.69 to 0.91). Cardiovascular death: 231 (7.4%) vs 261 (8.3%); HR 0.88 (95% CI 0.74 to 1.05). Total events and symptom burden were lower with dapagliflozin. Results were similar at an ejection fraction of 60% or more and below 60%, and with or without diabetes. Adverse events were similar in the two groups. |
Expert Commentary
My verdict is positive. In 6263 patients with heart failure and a left ventricular ejection fraction above 40%, dapagliflozin lowered the composite of worsening heart failure or cardiovascular death from 19.5% to 16.4% over a median of 2.3 years (hazard ratio 0.82; 95% CI 0.73 to 0.92). What I find most useful is the consistency. Results were similar in patients with an ejection fraction of 60% or more and in those below 60%, and with or without diabetes, so there is no obvious upper limit of ejection fraction at which the benefit disappears. Symptom burden was lower too, and adverse events were similar in the two groups. The limitation is that the gain came from worsening heart failure events (hazard ratio 0.79; 95% CI 0.69 to 0.91) and not from cardiovascular death, where the confidence interval crossed 1 (hazard ratio 0.88; 95% CI 0.74 to 1.05). This is a treatment that prevents decompensation, and it should be described to patients in those terms. The trial was funded by the manufacturer. Can I use this with my patients? Yes, in symptomatic heart failure with an ejection fraction above 40%, added to usual therapy. The next step should be making sure that eligible patients are actually offered it.
References
Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286. PMID: 36027570.

